ModiQuest Research Delivers Novel Therapeutic Antibodies For Rheumatoid Arthritis

05-Dec-2011 - Netherlands

Modiquest Research has successfully generated novel antibody therapeutic leads and diagnostics for rheumatoid arthritis (RA). Using its extensive antibody generation technology platform, which includes phage display and high throughput mouse hybridoma generation, the company identified specific anti-citrulline antibodies that demonstrate high efficacy levels in preclinical RA models.  

The company has been especially successful in supporting a variety of autoimmune disease projects in addition to rheumatoid arthritis, including multiple sclerosis, and lupus erythematosus. By using a combination of a unique technology service platform and a growing collection of immunological reagents for autoimmune disease research, ModiQuest provides the antibody expertise, as well as customised antigens, monoclonal antibodies and enzymes specifically designed for early diagnosis as well as therapeutic research.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous